Due to health issues, this site is no longer maintained and will be shut down shortly.

LN:ABC Abcam plc

Abcam plc, together with its subsidiaries, produces and distributes research-grade antibodies and associated protein research tools worldwide. The company primarily offers primary and secondary antibodies, biochemicals, isotype controls, flow cytometry multi-color selectors, kits, loading controls, lysates, peptides, proteins, slides, tags and cell markers, and tools and reagents. Its products are used in the areas of cancer, cardiovascular, cell biology, developmental biology, epigenetics and nuclear signaling, immunology, metabolism, microbiology, neuroscience, signal transduction, and stem cells, as well as in drug discovery products and services. Abcam plc also engages in sales and distribution, and financing and investing activities, as well as sells its products online. It offers validated antibodies and other binders, and assays to the research and clinical communities to help advance the understanding of biology and causes of disease. Abcam plc was founded in 1998 and is headquartered in Cambridge, the United Kingdom.This company has ADRs that trade in the U.S. as the symbol ABCM.

1,226.00 GBP
As of 12/13/2022

Security Information
Category1:  Global Equity
Category2:  Common stocks
Category3:  Developed markets ex-US
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  United Kingdom
Country of incorporation:  United Kingdom
IPO date:  11/03/2005
Stock exchange:    London Stock Exchange
Exchange country:   United Kingdom
Market cap:   2,635,110,912 GBP
Current dividend yield:   0.00%
Sedol:      B677469

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy